Guo X, Li J, Wang H M, Qiu J, Li Z, Huang F, Li J, Sun X D
Department of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China.
CanSino Biologics Inc., Tianjin 300457, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2024 Aug 6;58(8):1263-1277. doi: 10.3760/cma.j.cn112150-20230831-00147.
mRNA vaccine technology has made significant progress in recent years, especially with the large-scale application driven by the COVID-19 pandemic. Moderna and Pfizer/BioNTech vaccines have become central tools in the global fight against the virus, demonstrating the potential of the mRNA platform for rapid design, production, and strong immune responses. These vaccines showcase the unique advantages of rapid response and effective protection. At the same time, mRNA technology still faces challenges, such as stability and targeted delivery. Future research will focus on improving the stability and safety of mRNA vaccine and expanding its application to more infectious diseases and cancer treatments. This article reviews platforms of mRNA vaccine, vaccine design, development of delivery system, and the application of mRNA vaccines, in order to enhance the understanding of professionals and accelerate the layout of this technology in vaccine research and application in China.
近年来，mRNA疫苗技术取得了重大进展，特别是在新冠疫情推动下的大规模应用。Moderna和辉瑞/ BioNTech疫苗已成为全球抗击该病毒的核心工具，展示了mRNA平台在快速设计、生产和强大免疫反应方面的潜力。这些疫苗展现出快速响应和有效保护的独特优势。与此同时，mRNA技术仍面临挑战，如稳定性和靶向递送。未来的研究将集中于提高mRNA疫苗的稳定性和安全性，并将其应用扩展到更多传染病和癌症治疗领域。本文综述了mRNA疫苗的平台、疫苗设计、递送系统的发展以及mRNA疫苗的应用，以增进专业人士的理解，并加速该技术在中国疫苗研究和应用中的布局。
